235 related articles for article (PubMed ID: 10973126)
1. [Recommendations for the use of immunomodulatory drugs in multiple sclerosis: the BCTRIMS consensus] [Brazilian Committee for Treatment and Research in Multiple Sclerosis].
Tilbery CP; Moreira MA; Mendes MF; Lana-Peixoto MA
Arq Neuropsiquiatr; 2000 Sep; 58(3A):769-76. PubMed ID: 10973126
[TBL] [Abstract][Full Text] [Related]
2. To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes.
Frohman EM; Racke M; van Den Noort S
Arch Neurol; 2000 Jul; 57(7):930-2. PubMed ID: 10891973
[No Abstract] [Full Text] [Related]
3. Newer long-term treatments for multiple sclerosis.
Pryse-Phillips W
Clin Neurol Neurosurg; 2002 Jul; 104(3):265-71. PubMed ID: 12127666
[No Abstract] [Full Text] [Related]
4. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory treatment in multiple sclerosis: experience at a Brazilian center with 390 patients.
Tilbery CP; Mendes MF; Oliveira BE; Thomaz RB; Kelian GR
Arq Neuropsiquiatr; 2006 Mar; 64(1):51-4. PubMed ID: 16622553
[TBL] [Abstract][Full Text] [Related]
6. [Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region].
Spirin NN; Kasatkin DS; Stepanov IO; Shipova EG; Baranova NS
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(8):27-33. PubMed ID: 23096035
[TBL] [Abstract][Full Text] [Related]
7. Multiple sclerosis treatment 2001.
Rolak LA
Neurol Clin; 2001 Feb; 19(1):107-18. PubMed ID: 11471759
[TBL] [Abstract][Full Text] [Related]
8. [Possibilities and limits of immunotherapy in multiple sclerosis. Inflammatory and degenerative aspects of the disease require a new pathogenetic concept].
Kornhuber ME; Zierz S
Nervenarzt; 2003 Jun; 74(6):537-8; discussion 539. PubMed ID: 12799792
[No Abstract] [Full Text] [Related]
9. [Current concepts on the use of some immunomodulatory drugs in the treatment of multiple sclerosis].
Correale J; Cristiano E
Medicina (B Aires); 2001; 61(4):470-80. PubMed ID: 11563177
[TBL] [Abstract][Full Text] [Related]
10. Comment on Shuhaibar et al.: Favourable effect of immunomodulator therapy on bone mineral density in multiple sclerosis.
Kampman MT; Steffensen LH
Ir J Med Sci; 2009 Jun; 178(2):235-6; author reply 237-8. PubMed ID: 19184608
[No Abstract] [Full Text] [Related]
11. Contemporary immunomodulatory therapy for multiple sclerosis.
Rudick RA
J Neuroophthalmol; 2001 Dec; 21(4):284-91. PubMed ID: 11756861
[TBL] [Abstract][Full Text] [Related]
12. International consensus statement on the use of disease-modifying agents in multiple sclerosis.
Freedman MS; Blumhardt LD; Brochet B; Comi G; Noseworthy JH; Sandberg-Wollheim M; Soelberg SP;
Mult Scler; 2002 Feb; 8(1):19-23. PubMed ID: 11936483
[TBL] [Abstract][Full Text] [Related]
13. Interferon-beta1b for the treatment of multiple sclerosis.
Lam S; Wang S; Gottesman M
Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1111-7. PubMed ID: 18680445
[TBL] [Abstract][Full Text] [Related]
14. Key issues in the diagnosis and treatment of multiple sclerosis. An overview.
O'Connor P;
Neurology; 2002 Sep; 59(6 Suppl 3):S1-33. PubMed ID: 12448786
[No Abstract] [Full Text] [Related]
15. Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics.
Rudick RA
Arch Neurol; 1999 Sep; 56(9):1079-84. PubMed ID: 10488808
[TBL] [Abstract][Full Text] [Related]
16. Factors leading patients to discontinue multiple sclerosis therapies.
Daugherty KK; Butler JS; Mattingly M; Ryan M
J Am Pharm Assoc (2003); 2005; 45(3):371-5. PubMed ID: 15991759
[TBL] [Abstract][Full Text] [Related]
17. [A comparative analysis of rebif 22-mcg and copaxone efficacy in multiple sclerosis].
Zavalishin IA; Peresedova AV; Stoĭda NI; Rebrova Oi; Zakharova MN; Adarcheva LS; Niazbekova AS; Askarova LSh; Baĭdina EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2006; Spec No 3():111-5. PubMed ID: 17172245
[TBL] [Abstract][Full Text] [Related]
18. [Problems and prospects of beta-interferon and copaxone++ application in the treatment of multiple sclerosis].
Gusev EI; Boĭko AN; Pozer Ch
Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(4):33-6. PubMed ID: 10319395
[No Abstract] [Full Text] [Related]
19. [Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)].
Federal service on surveillance in healthcare and social development (Roszdravnadzor)
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):93-8. PubMed ID: 21916163
[No Abstract] [Full Text] [Related]
20. [The BCTRIMS expanded consensus on treatment of multiple sclerosis: II. The evidences for the use of glucocorticoids and immunomodulatory treatments].
Moreira MA; Lana-Peixoto MA; Callegaro D; Haussen SR; Gama PD; Gabbai AA; Rocha FC; Lino AM;
Arq Neuropsiquiatr; 2002 Sep; 60(3-B):875-80. PubMed ID: 12364966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
